Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKY-D trial of subcutaneous ketamine for youth major depressive disorder
ACTRN12619000683134Phase 3Completed
- Sponsor
- Orygen
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Subcutaneous ketamine with Subcutaneous midazolam control (2 arms). Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale. Started Jul 2019; status: completed.
02
Drugs
ketaminemidazolam
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12619000683134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000683134.